AU2012323316B2 - CD40L-specific Tn3-derived scaffolds and methods of use thereof - Google Patents

Info

Publication number

AU2012323316B2

AU2012323316B2 AU2012323316A AU2012323316A AU2012323316B2 AU 2012323316 B2 AU2012323316 B2 AU 2012323316B2 AU 2012323316 A AU2012323316 A AU 2012323316A AU 2012323316 A AU2012323316 A AU 2012323316A AU 2012323316 B2 AU2012323316 B2 AU 2012323316B2

Authority

AU

Australia

Prior art keywords

scaffold

cd40l

seq

sequence

loop

Prior art date

2011-10-11

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• Discuss

• 102100032937 CD40 ligand Human genes 0.000 title claims abstract description 518
• 108010029697 CD40 Ligand Proteins 0.000 title claims abstract description 516
• 238000000034 method Methods 0.000 title claims description 125
• 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 27
• 239000003814 drug Substances 0.000 claims abstract description 14
• 239000000178 monomer Substances 0.000 claims description 275
• 125000000539 amino acid group Chemical group 0.000 claims description 154
• 230000027455 binding Effects 0.000 claims description 132
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 125
• 108091006905 Human Serum Albumin Proteins 0.000 claims description 123
• 102000008100 Human Serum Albumin Human genes 0.000 claims description 123
• 238000006467 substitution reaction Methods 0.000 claims description 104
• 108090000623 proteins and genes Proteins 0.000 claims description 95
• 102000004169 proteins and genes Human genes 0.000 claims description 87
• 235000018102 proteins Nutrition 0.000 claims description 80
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 78
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 76
• 229920001184 polypeptide Polymers 0.000 claims description 74
• 235000001014 amino acid Nutrition 0.000 claims description 73
• 239000012634 fragment Substances 0.000 claims description 59
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 54
• 101100059511 Homo sapiens CD40LG gene Proteins 0.000 claims description 53
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 53
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 45
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 45
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 44
• 235000004279 alanine Nutrition 0.000 claims description 44
• 239000004471 Glycine Substances 0.000 claims description 42
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 42
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 40
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 40
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 39
• 235000009582 asparagine Nutrition 0.000 claims description 39
• 229960001230 asparagine Drugs 0.000 claims description 39
• 235000003704 aspartic acid Nutrition 0.000 claims description 39
• CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical class N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 39
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 39
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 38
• 235000013922 glutamic acid Nutrition 0.000 claims description 38
• 239000004220 glutamic acid Substances 0.000 claims description 38
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 36
• 239000004472 Lysine Substances 0.000 claims description 35
• 229960000310 isoleucine Drugs 0.000 claims description 35
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 35
• 239000000203 mixture Substances 0.000 claims description 35
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 34
• 101150013553 CD40 gene Proteins 0.000 claims description 33
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 33
• COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical class N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 33
• 229920001223 polyethylene glycol Polymers 0.000 claims description 33
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 31
• 239000004473 Threonine Substances 0.000 claims description 31
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 30
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 29
• 230000000694 effects Effects 0.000 claims description 29
• 239000004474 valine Substances 0.000 claims description 29
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 28
• 239000002202 Polyethylene glycol Substances 0.000 claims description 28
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 28
• 150000007523 nucleic acids Chemical class 0.000 claims description 27
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 26
• 150000001875 compounds Chemical class 0.000 claims description 24
• 102000039446 nucleic acids Human genes 0.000 claims description 24
• 108020004707 nucleic acids Proteins 0.000 claims description 24
• 230000001976 improved effect Effects 0.000 claims description 22
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 21
• 239000004475 Arginine Substances 0.000 claims description 20
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 20
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 20
• 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 17
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 16
• 239000013598 vector Substances 0.000 claims description 15
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 14
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 14
• 102000005962 receptors Human genes 0.000 claims description 14
• 108020003175 receptors Proteins 0.000 claims description 14
• 239000003446 ligand Substances 0.000 claims description 13
• 206010025135 lupus erythematosus Diseases 0.000 claims description 13
• 102000009027 Albumins Human genes 0.000 claims description 11
• 108010088751 Albumins Proteins 0.000 claims description 11
• 230000001404 mediated effect Effects 0.000 claims description 11
• 238000002560 therapeutic procedure Methods 0.000 claims description 11
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 10
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 10
• 230000009471 action Effects 0.000 claims description 10
• 239000013604 expression vector Substances 0.000 claims description 10
• 229930182817 methionine Natural products 0.000 claims description 10
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 10
• 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 9
• 201000004681 Psoriasis Diseases 0.000 claims description 9
• 231100000599 cytotoxic agent Toxicity 0.000 claims description 8
• 229920000642 polymer Polymers 0.000 claims description 8
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 8
• 208000011231 Crohn disease Diseases 0.000 claims description 7
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 7
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 7
• 208000021386 Sjogren Syndrome Diseases 0.000 claims description 7
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 7
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 7
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 7
• 239000011616 biotin Substances 0.000 claims description 7
• 229960002685 biotin Drugs 0.000 claims description 7
• 235000020958 biotin Nutrition 0.000 claims description 7
• 201000006417 multiple sclerosis Diseases 0.000 claims description 7
• 102000004190 Enzymes Human genes 0.000 claims description 6
• 108090000790 Enzymes Proteins 0.000 claims description 6
• 208000001640 Fibromyalgia Diseases 0.000 claims description 6
• 208000015023 Graves' disease Diseases 0.000 claims description 6
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 6
• 206010034277 Pemphigoid Diseases 0.000 claims description 6
• 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 6
• 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 6
• 206010063837 Reperfusion injury Diseases 0.000 claims description 6
• 206010040047 Sepsis Diseases 0.000 claims description 6
• 206010047115 Vasculitis Diseases 0.000 claims description 6
• 229940079593 drug Drugs 0.000 claims description 6
• 239000012216 imaging agent Substances 0.000 claims description 6
• 210000004379 membrane Anatomy 0.000 claims description 6
• 239000012528 membrane Substances 0.000 claims description 6
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 6
• 230000011664 signaling Effects 0.000 claims description 6
• 102000004127 Cytokines Human genes 0.000 claims description 5
• 108090000695 Cytokines Proteins 0.000 claims description 5
• 206010003246 arthritis Diseases 0.000 claims description 5
• 208000037976 chronic inflammation Diseases 0.000 claims description 5
• 230000006020 chronic inflammation Effects 0.000 claims description 5
• 239000002254 cytotoxic agent Substances 0.000 claims description 5
• 229940127089 cytotoxic agent Drugs 0.000 claims description 5
• 150000002519 isoleucine derivatives Chemical class 0.000 claims description 5
• 108020001580 protein domains Proteins 0.000 claims description 5
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 5
• 210000001519 tissue Anatomy 0.000 claims description 5
• 201000001320 Atherosclerosis Diseases 0.000 claims description 4
• 208000015943 Coeliac disease Diseases 0.000 claims description 4
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
• 206010018364 Glomerulonephritis Diseases 0.000 claims description 4
• 206010040070 Septic Shock Diseases 0.000 claims description 4
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
• 238000002512 chemotherapy Methods 0.000 claims description 4
• 238000009169 immunotherapy Methods 0.000 claims description 4
• 210000000056 organ Anatomy 0.000 claims description 4
• 230000002285 radioactive effect Effects 0.000 claims description 4
• 230000004044 response Effects 0.000 claims description 4
• 238000002054 transplantation Methods 0.000 claims description 4
• 208000008190 Agammaglobulinemia Diseases 0.000 claims description 3
• 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims description 3
• 206010002199 Anaphylactic shock Diseases 0.000 claims description 3
• 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 3
• 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 3
• 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims description 3
• 208000023328 Basedow disease Diseases 0.000 claims description 3
• 208000009137 Behcet syndrome Diseases 0.000 claims description 3
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 3
• 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 3
• 201000002829 CREST Syndrome Diseases 0.000 claims description 3
• 208000031229 Cardiomyopathies Diseases 0.000 claims description 3
• 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims description 3
• 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims description 3
• 208000011038 Cold agglutinin disease Diseases 0.000 claims description 3
• 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims description 3
• 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims description 3
• 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
• 201000004624 Dermatitis Diseases 0.000 claims description 3
• 206010012468 Dermatitis herpetiformis Diseases 0.000 claims description 3
• 206010014824 Endotoxic shock Diseases 0.000 claims description 3
• 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims description 3
• 208000007465 Giant cell arteritis Diseases 0.000 claims description 3
• 208000010412 Glaucoma Diseases 0.000 claims description 3
• 206010018498 Goitre Diseases 0.000 claims description 3
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
• 208000003807 Graves Disease Diseases 0.000 claims description 3
• 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 3
• 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims description 3
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 3
• 208000003456 Juvenile Arthritis Diseases 0.000 claims description 3
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 3
• 208000027530 Meniere disease Diseases 0.000 claims description 3
• 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 3
• 201000011152 Pemphigus Diseases 0.000 claims description 3
• 208000031845 Pernicious anaemia Diseases 0.000 claims description 3
• 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims description 3
• 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 3
• 208000033464 Reiter syndrome Diseases 0.000 claims description 3
• 206010038923 Retinopathy Diseases 0.000 claims description 3
• 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 3
• 206010039710 Scleroderma Diseases 0.000 claims description 3
• 206010072148 Stiff-Person syndrome Diseases 0.000 claims description 3
• 208000001106 Takayasu Arteritis Diseases 0.000 claims description 3
• 206010046851 Uveitis Diseases 0.000 claims description 3
• 206010047112 Vasculitides Diseases 0.000 claims description 3
• 206010047642 Vitiligo Diseases 0.000 claims description 3
• 210000004100 adrenal gland Anatomy 0.000 claims description 3
• 206010064930 age-related macular degeneration Diseases 0.000 claims description 3
• 208000004631 alopecia areata Diseases 0.000 claims description 3
• 208000003455 anaphylaxis Diseases 0.000 claims description 3
• 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 3
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 3
• 208000006424 autoimmune oophoritis Diseases 0.000 claims description 3
• 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 claims description 3
• 208000000594 bullous pemphigoid Diseases 0.000 claims description 3
• 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims description 3
• 201000003278 cryoglobulinemia Diseases 0.000 claims description 3
• 201000001981 dermatomyositis Diseases 0.000 claims description 3
• 206010012601 diabetes mellitus Diseases 0.000 claims description 3
• 238000002651 drug therapy Methods 0.000 claims description 3
• 206010014665 endocarditis Diseases 0.000 claims description 3
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 3
• 201000011066 hemangioma Diseases 0.000 claims description 3
• 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 3
• 229920000592 inorganic polymer Polymers 0.000 claims description 3
• 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 3
• 208000028867 ischemia Diseases 0.000 claims description 3
• 201000011486 lichen planus Diseases 0.000 claims description 3
• 208000002780 macular degeneration Diseases 0.000 claims description 3
• 206010028417 myasthenia gravis Diseases 0.000 claims description 3
• 201000003142 neovascular glaucoma Diseases 0.000 claims description 3
• 201000001119 neuropathy Diseases 0.000 claims description 3
• 230000007823 neuropathy Effects 0.000 claims description 3
• 201000005737 orchitis Diseases 0.000 claims description 3
• 229920000620 organic polymer Polymers 0.000 claims description 3
• 201000001976 pemphigus vulgaris Diseases 0.000 claims description 3
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
• 206010034674 peritonitis Diseases 0.000 claims description 3
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
• 201000006292 polyarteritis nodosa Diseases 0.000 claims description 3
• 208000005987 polymyositis Diseases 0.000 claims description 3
• 238000001959 radiotherapy Methods 0.000 claims description 3
• 208000002574 reactive arthritis Diseases 0.000 claims description 3
• 201000000306 sarcoidosis Diseases 0.000 claims description 3
• 208000013223 septicemia Diseases 0.000 claims description 3
• 208000020431 spinal cord injury Diseases 0.000 claims description 3
• 208000011580 syndromic disease Diseases 0.000 claims description 3
• 206010043207 temporal arteritis Diseases 0.000 claims description 3
• 230000002123 temporal effect Effects 0.000 claims description 3
• 239000003053 toxin Substances 0.000 claims description 3
• 231100000765 toxin Toxicity 0.000 claims description 3
• 108700012359 toxins Proteins 0.000 claims description 3
• 238000011374 additional therapy Methods 0.000 claims description 2
• 238000001815 biotherapy Methods 0.000 claims description 2
• 239000003246 corticosteroid Substances 0.000 claims description 2
• 238000012258 culturing Methods 0.000 claims description 2
• 229940126586 small molecule drug Drugs 0.000 claims description 2
• 150000002614 leucines Chemical class 0.000 claims 3
• 125000000341 threoninyl group Chemical class [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
• 125000000404 glutamine group Chemical class N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 2
• 150000001294 alanine derivatives Chemical class 0.000 claims 1
• 150000003680 valines Chemical class 0.000 claims 1
• 230000001965 increasing effect Effects 0.000 abstract description 27
• 230000001225 therapeutic effect Effects 0.000 abstract description 9
• 229940124597 therapeutic agent Drugs 0.000 abstract description 4
• 230000000069 prophylactic effect Effects 0.000 abstract description 3
• 239000000032 diagnostic agent Substances 0.000 abstract 1
• 229940039227 diagnostic agent Drugs 0.000 abstract 1
• 210000004027 cell Anatomy 0.000 description 126
• 239000013078 crystal Substances 0.000 description 55
• 229940024606 amino acid Drugs 0.000 description 54
• 150000001413 amino acids Chemical class 0.000 description 53
• 238000003556 assay Methods 0.000 description 50
• 230000014509 gene expression Effects 0.000 description 43
• 241001529936 Murinae Species 0.000 description 40
• 239000000427 antigen Substances 0.000 description 39
• 102000036639 antigens Human genes 0.000 description 38
• 108091007433 antigens Proteins 0.000 description 38
• 230000009824 affinity maturation Effects 0.000 description 37
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 36
• 210000002381 plasma Anatomy 0.000 description 36
• 210000003719 b-lymphocyte Anatomy 0.000 description 30
• 230000004927 fusion Effects 0.000 description 29
• 201000010099 disease Diseases 0.000 description 25
• 230000006870 function Effects 0.000 description 25
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 24
• 210000001744 T-lymphocyte Anatomy 0.000 description 23
• 238000011282 treatment Methods 0.000 description 23
• 238000001727 in vivo Methods 0.000 description 22
• 239000002953 phosphate buffered saline Substances 0.000 description 21
• 238000000746 purification Methods 0.000 description 21
• 230000035772 mutation Effects 0.000 description 20
• 239000000047 product Substances 0.000 description 19
• 210000002966 serum Anatomy 0.000 description 19
• 102000007000 Tenascin Human genes 0.000 description 17
• 108010008125 Tenascin Proteins 0.000 description 17
• 230000005764 inhibitory process Effects 0.000 description 17
• 230000003993 interaction Effects 0.000 description 17
• 108020004414 DNA Proteins 0.000 description 15
• 108091033319 polynucleotide Proteins 0.000 description 15
• 102000040430 polynucleotide Human genes 0.000 description 15
• 239000002157 polynucleotide Substances 0.000 description 15
• 108020004705 Codon Proteins 0.000 description 14
• 241001465754 Metazoa Species 0.000 description 14
• 230000004913 activation Effects 0.000 description 14
• 238000007792 addition Methods 0.000 description 14
• 238000000338 in vitro Methods 0.000 description 14
• 238000004519 manufacturing process Methods 0.000 description 14
• 239000000523 sample Substances 0.000 description 14
• 102000007562 Serum Albumin Human genes 0.000 description 13
• 108010071390 Serum Albumin Proteins 0.000 description 13
• 102220105280 rs879254406 Human genes 0.000 description 13
• 239000012636 effector Substances 0.000 description 12
• 238000002703 mutagenesis Methods 0.000 description 12
• 231100000350 mutagenesis Toxicity 0.000 description 12
• 102220080600 rs797046116 Human genes 0.000 description 12
• 239000003795 chemical substances by application Substances 0.000 description 11
• 230000021615 conjugation Effects 0.000 description 11
• 239000008194 pharmaceutical composition Substances 0.000 description 11
• 238000004458 analytical method Methods 0.000 description 10
• 230000004071 biological effect Effects 0.000 description 10
• 238000012217 deletion Methods 0.000 description 10
• 230000037430 deletion Effects 0.000 description 10
• 208000035475 disorder Diseases 0.000 description 10
• 102000037865 fusion proteins Human genes 0.000 description 10
• 108020001507 fusion proteins Proteins 0.000 description 10
• 238000005457 optimization Methods 0.000 description 10
• 230000008569 process Effects 0.000 description 10
• 239000013638 trimer Substances 0.000 description 10
• 101000666340 Homo sapiens Tenascin Proteins 0.000 description 9
• 241000699666 Mus <mouse, genus> Species 0.000 description 9
• 108091034117 Oligonucleotide Proteins 0.000 description 9
• 230000002776 aggregation Effects 0.000 description 9
• 238000004220 aggregation Methods 0.000 description 9
• 230000004075 alteration Effects 0.000 description 9
• 238000000113 differential scanning calorimetry Methods 0.000 description 9
• 102000057345 human TNC Human genes 0.000 description 9
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
• 230000006872 improvement Effects 0.000 description 9
• 208000027866 inflammatory disease Diseases 0.000 description 9
• 238000004091 panning Methods 0.000 description 9
• 230000002441 reversible effect Effects 0.000 description 9
• 238000012216 screening Methods 0.000 description 9
• 239000000243 solution Substances 0.000 description 9
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
• 239000011230 binding agent Substances 0.000 description 8
• 239000003153 chemical reaction reagent Substances 0.000 description 8
• 235000018417 cysteine Nutrition 0.000 description 8
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 8
• 230000003053 immunization Effects 0.000 description 8
• 238000002649 immunization Methods 0.000 description 8
• 230000002401 inhibitory effect Effects 0.000 description 8
• 125000001909 leucine group Chemical class [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
• 239000013642 negative control Substances 0.000 description 8
• 125000003729 nucleotide group Chemical group 0.000 description 8
• 208000024891 symptom Diseases 0.000 description 8
• 150000003588 threonines Chemical class 0.000 description 8
• 241000588724 Escherichia coli Species 0.000 description 7
• 108060003951 Immunoglobulin Proteins 0.000 description 7
• 241000699670 Mus sp. Species 0.000 description 7
• 241001494479 Pecora Species 0.000 description 7
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 7
• 210000004899 c-terminal region Anatomy 0.000 description 7
• 238000006243 chemical reaction Methods 0.000 description 7
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 7
• 230000007423 decrease Effects 0.000 description 7
• 230000003247 decreasing effect Effects 0.000 description 7
• 238000006471 dimerization reaction Methods 0.000 description 7
• 210000003743 erythrocyte Anatomy 0.000 description 7
• 210000001280 germinal center Anatomy 0.000 description 7
• 102000018358 immunoglobulin Human genes 0.000 description 7
• 239000002773 nucleotide Substances 0.000 description 7
• 238000002823 phage display Methods 0.000 description 7
• 230000002829 reductive effect Effects 0.000 description 7
• 238000001542 size-exclusion chromatography Methods 0.000 description 7
• 238000012360 testing method Methods 0.000 description 7
• 238000005406 washing Methods 0.000 description 7
• 108091035707 Consensus sequence Proteins 0.000 description 6
• 238000013459 approach Methods 0.000 description 6
• 230000001363 autoimmune Effects 0.000 description 6
• 239000011324 bead Substances 0.000 description 6
• 238000013461 design Methods 0.000 description 6
• 238000002474 experimental method Methods 0.000 description 6
• 238000003384 imaging method Methods 0.000 description 6
• 238000002794 lymphocyte assay Methods 0.000 description 6
• 238000003259 recombinant expression Methods 0.000 description 6
• 238000011160 research Methods 0.000 description 6
• 238000007423 screening assay Methods 0.000 description 6
• 239000007787 solid Substances 0.000 description 6
• 230000000638 stimulation Effects 0.000 description 6
• -1 tripeptides Proteins 0.000 description 6
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
• 108010087819 Fc receptors Proteins 0.000 description 5
• 102000009109 Fc receptors Human genes 0.000 description 5
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
• 239000005089 Luciferase Substances 0.000 description 5
• 241000282567 Macaca fascicularis Species 0.000 description 5
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
• 239000005557 antagonist Substances 0.000 description 5
• 210000000612 antigen-presenting cell Anatomy 0.000 description 5
• 125000004429 atom Chemical group 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 238000011161 development Methods 0.000 description 5
• 230000018109 developmental process Effects 0.000 description 5
• 230000002255 enzymatic effect Effects 0.000 description 5
• 229940088598 enzyme Drugs 0.000 description 5
• 230000013595 glycosylation Effects 0.000 description 5
• 238000006206 glycosylation reaction Methods 0.000 description 5
• 230000005847 immunogenicity Effects 0.000 description 5
• 238000011065 in-situ storage Methods 0.000 description 5
• 238000011534 incubation Methods 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 239000002609 medium Substances 0.000 description 5
• 108020004999 messenger RNA Proteins 0.000 description 5
• 238000002887 multiple sequence alignment Methods 0.000 description 5
• 238000006384 oligomerization reaction Methods 0.000 description 5
• 239000013612 plasmid Substances 0.000 description 5
• 210000004180 plasmocyte Anatomy 0.000 description 5
• 229920000136 polysorbate Polymers 0.000 description 5
• 230000003389 potentiating effect Effects 0.000 description 5
• 230000002265 prevention Effects 0.000 description 5
• 230000008685 targeting Effects 0.000 description 5
• XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 4
• XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 4
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 4
• 102000002090 Fibronectin type III Human genes 0.000 description 4
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 4
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 4
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
• 230000004988 N-glycosylation Effects 0.000 description 4
• 206010028980 Neoplasm Diseases 0.000 description 4
• 241000283973 Oryctolagus cuniculus Species 0.000 description 4
• 239000000556 agonist Substances 0.000 description 4
• 230000000903 blocking effect Effects 0.000 description 4
• 201000011510 cancer Diseases 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
• 238000003501 co-culture Methods 0.000 description 4
• 230000000295 complement effect Effects 0.000 description 4
• 239000012228 culture supernatant Substances 0.000 description 4
• 238000013500 data storage Methods 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 238000001514 detection method Methods 0.000 description 4
• 238000010790 dilution Methods 0.000 description 4
• 239000012895 dilution Substances 0.000 description 4
• 238000010494 dissociation reaction Methods 0.000 description 4
• 230000005593 dissociations Effects 0.000 description 4
• 150000002309 glutamines Chemical class 0.000 description 4
• 230000002757 inflammatory effect Effects 0.000 description 4
• 238000004255 ion exchange chromatography Methods 0.000 description 4
• 235000013336 milk Nutrition 0.000 description 4
• 239000008267 milk Substances 0.000 description 4
• 210000004080 milk Anatomy 0.000 description 4
• 238000012544 monitoring process Methods 0.000 description 4
• 210000004986 primary T-cell Anatomy 0.000 description 4
• 238000000159 protein binding assay Methods 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 102220267326 rs371110225 Human genes 0.000 description 4
• 150000003839 salts Chemical class 0.000 description 4
• 238000010963 scalable process Methods 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 238000001890 transfection Methods 0.000 description 4
• 241000894006 Bacteria Species 0.000 description 3
• 241000283707 Capra Species 0.000 description 3
• 102000014914 Carrier Proteins Human genes 0.000 description 3
• 102000000844 Cell Surface Receptors Human genes 0.000 description 3
• 108010001857 Cell Surface Receptors Proteins 0.000 description 3
• 208000035473 Communicable disease Diseases 0.000 description 3
• 206010061818 Disease progression Diseases 0.000 description 3
• 108050009401 Fibronectin type III Proteins 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 3
• 108091028043 Nucleic acid sequence Proteins 0.000 description 3
• 238000012408 PCR amplification Methods 0.000 description 3
• 239000004365 Protease Substances 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• 125000003295 alanine group Chemical class N[C@@H](C)C(=O)* 0.000 description 3
• 230000003321 amplification Effects 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 230000005875 antibody response Effects 0.000 description 3
• 210000003651 basophil Anatomy 0.000 description 3
• 108091008324 binding proteins Proteins 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 3
• 229960003669 carbenicillin Drugs 0.000 description 3
• 230000011748 cell maturation Effects 0.000 description 3
• 230000004663 cell proliferation Effects 0.000 description 3
• 230000001684 chronic effect Effects 0.000 description 3
• 230000001268 conjugating effect Effects 0.000 description 3
• 238000010276 construction Methods 0.000 description 3
• 238000011443 conventional therapy Methods 0.000 description 3
• 231100000433 cytotoxic Toxicity 0.000 description 3
• 230000001472 cytotoxic effect Effects 0.000 description 3
• 239000002619 cytotoxin Substances 0.000 description 3
• SSJJWVREPZVNBF-DGXVIIAXSA-N dG10 Chemical compound C1=NC(C(NC(N)=N2)=O)=C2N1[C@H](O[C@@H]1COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)C[C@@H]1OP(O)(=O)OC[C@@H](O1)[C@@H](O)C[C@@H]1N1C(N=C(NC2=O)N)=C2N=C1 SSJJWVREPZVNBF-DGXVIIAXSA-N 0.000 description 3
• 238000003745 diagnosis Methods 0.000 description 3
• 239000000539 dimer Substances 0.000 description 3
• 230000005750 disease progression Effects 0.000 description 3
• 238000010828 elution Methods 0.000 description 3
• 125000000524 functional group Chemical group 0.000 description 3
• 150000004676 glycans Chemical class 0.000 description 3
• 210000003630 histaminocyte Anatomy 0.000 description 3
• 230000002209 hydrophobic effect Effects 0.000 description 3
• 210000002865 immune cell Anatomy 0.000 description 3
• 230000028993 immune response Effects 0.000 description 3
• 239000003550 marker Substances 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 201000008383 nephritis Diseases 0.000 description 3
• 210000000440 neutrophil Anatomy 0.000 description 3
• 238000003199 nucleic acid amplification method Methods 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 210000004623 platelet-rich plasma Anatomy 0.000 description 3
• 239000013641 positive control Substances 0.000 description 3
• 230000006337 proteolytic cleavage Effects 0.000 description 3
• 238000011084 recovery Methods 0.000 description 3
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
• 241000894007 species Species 0.000 description 3
• 230000009870 specific binding Effects 0.000 description 3
• 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
• 230000004083 survival effect Effects 0.000 description 3
• 125000003396 thiol group Chemical group [H]S* 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 241001515965 unidentified phage Species 0.000 description 3
• 230000003827 upregulation Effects 0.000 description 3
• 239000003981 vehicle Substances 0.000 description 3
• 238000002424 x-ray crystallography Methods 0.000 description 3
• 102000011690 Adiponectin Human genes 0.000 description 2
• 108010076365 Adiponectin Proteins 0.000 description 2
• 235000014469 Bacillus subtilis Nutrition 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 102100021935 C-C motif chemokine 26 Human genes 0.000 description 2
• 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• 101710112752 Cytotoxin Proteins 0.000 description 2
• SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
• 102000053602 DNA Human genes 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• 238000012286 ELISA Assay Methods 0.000 description 2
• ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
• 241000672609 Escherichia coli BL21 Species 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 208000009386 Experimental Arthritis Diseases 0.000 description 2
• 108010067306 Fibronectins Proteins 0.000 description 2
• 102000016359 Fibronectins Human genes 0.000 description 2
• 101710154606 Hemagglutinin Proteins 0.000 description 2
• 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 2
• 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 2
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
• 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 2
• 108060001084 Luciferase Proteins 0.000 description 2
• 208000005777 Lupus Nephritis Diseases 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 102000018697 Membrane Proteins Human genes 0.000 description 2
• 108010052285 Membrane Proteins Proteins 0.000 description 2
• 101100288142 Mus musculus Klkb1 gene Proteins 0.000 description 2
• 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
• 108010038807 Oligopeptides Proteins 0.000 description 2
• 102000015636 Oligopeptides Human genes 0.000 description 2
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 229920001213 Polysorbate 20 Polymers 0.000 description 2
• 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 2
• 101710176177 Protein A56 Proteins 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
• 101710204410 Scaffold protein Proteins 0.000 description 2
• 108020004682 Single-Stranded DNA Proteins 0.000 description 2
• 108010090804 Streptavidin Proteins 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• 238000000333 X-ray scattering Methods 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
• 229940121363 anti-inflammatory agent Drugs 0.000 description 2
• 239000002260 anti-inflammatory agent Substances 0.000 description 2
• 239000002111 antiemetic agent Substances 0.000 description 2
• 229940125683 antiemetic agent Drugs 0.000 description 2
• 229940121375 antifungal agent Drugs 0.000 description 2
• 239000003429 antifungal agent Substances 0.000 description 2
• 239000003443 antiviral agent Substances 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 239000004305 biphenyl Substances 0.000 description 2
• 150000001720 carbohydrates Chemical group 0.000 description 2
• 238000000423 cell based assay Methods 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 230000003915 cell function Effects 0.000 description 2
• 230000005754 cellular signaling Effects 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 230000006957 competitive inhibition Effects 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 230000000139 costimulatory effect Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 239000003431 cross linking reagent Substances 0.000 description 2
• 239000002178 crystalline material Substances 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 230000003013 cytotoxicity Effects 0.000 description 2
• 231100000135 cytotoxicity Toxicity 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 230000022811 deglycosylation Effects 0.000 description 2
• 210000004443 dendritic cell Anatomy 0.000 description 2
• 230000001627 detrimental effect Effects 0.000 description 2
• 238000002050 diffraction method Methods 0.000 description 2
• 238000009792 diffusion process Methods 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 239000002158 endotoxin Substances 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 210000003979 eosinophil Anatomy 0.000 description 2
• 229930182830 galactose Natural products 0.000 description 2
• 239000004120 green S Substances 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 238000003018 immunoassay Methods 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 238000005304 joining Methods 0.000 description 2
• 238000012417 linear regression Methods 0.000 description 2
• 238000004020 luminiscence type Methods 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 210000004962 mammalian cell Anatomy 0.000 description 2
• 238000007726 management method Methods 0.000 description 2
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 229960004857 mitomycin Drugs 0.000 description 2
• 210000000822 natural killer cell Anatomy 0.000 description 2
• 108010068617 neonatal Fc receptor Proteins 0.000 description 2
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
• 230000000737 periodic effect Effects 0.000 description 2
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 238000012913 prioritisation Methods 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 235000019419 proteases Nutrition 0.000 description 2
• 230000006916 protein interaction Effects 0.000 description 2
• 238000002005 protein protein interaction detection Methods 0.000 description 2
• 238000002762 protein-protein interaction assay Methods 0.000 description 2
• 230000002797 proteolythic effect Effects 0.000 description 2
• 208000005069 pulmonary fibrosis Diseases 0.000 description 2
• 238000002708 random mutagenesis Methods 0.000 description 2
• 230000006798 recombination Effects 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 108091008146 restriction endonucleases Proteins 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• 239000012146 running buffer Substances 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 125000006850 spacer group Chemical group 0.000 description 2
• 230000002269 spontaneous effect Effects 0.000 description 2
• 239000011232 storage material Substances 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• 125000002987 valine group Chemical class [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
• 238000005303 weighing Methods 0.000 description 2
• HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
• 229960002555 zidovudine Drugs 0.000 description 2
• XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
• UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
• GODZNYBQGNSJJN-UHFFFAOYSA-N 1-aminoethane-1,2-diol Chemical compound NC(O)CO GODZNYBQGNSJJN-UHFFFAOYSA-N 0.000 description 1
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
• JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
• FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
• UKYNESNNFCHAEV-UHFFFAOYSA-N 3,4-dibromooxolane-2,5-dione Chemical compound BrC1C(Br)C(=O)OC1=O UKYNESNNFCHAEV-UHFFFAOYSA-N 0.000 description 1
• YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
• RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
• 208000030090 Acute Disease Diseases 0.000 description 1
• 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
• 229930183010 Amphotericin Natural products 0.000 description 1
• QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
• APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
• 235000002198 Annona diversifolia Nutrition 0.000 description 1
• 206010003011 Appendicitis Diseases 0.000 description 1
• 102000007347 Apyrase Human genes 0.000 description 1
• 108010007730 Apyrase Proteins 0.000 description 1
• 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 1
• 208000036487 Arthropathies Diseases 0.000 description 1
• 102100039341 Atrial natriuretic peptide receptor 2 Human genes 0.000 description 1
• 101710102159 Atrial natriuretic peptide receptor 2 Proteins 0.000 description 1
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
• NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
• 108091008875 B cell receptors Proteins 0.000 description 1
• 230000003844 B-cell-activation Effects 0.000 description 1
• 108010001478 Bacitracin Proteins 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000282832 Camelidae Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 101710132601 Capsid protein Proteins 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 229930186147 Cephalosporin Natural products 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 101710094648 Coat protein Proteins 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 206010009895 Colitis ischaemic Diseases 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 108010069112 Complement System Proteins Proteins 0.000 description 1
• 102000000989 Complement System Proteins Human genes 0.000 description 1
• 239000004971 Cross linker Substances 0.000 description 1
• DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
• DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 108010092160 Dactinomycin Proteins 0.000 description 1
• 208000019505 Deglutition disease Diseases 0.000 description 1
• 108010016626 Dipeptides Proteins 0.000 description 1
• 206010013554 Diverticulum Diseases 0.000 description 1
• 208000008279 Dumping Syndrome Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 description 1
• IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
• 208000010201 Exanthema Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 208000007882 Gastritis Diseases 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
• 229930182566 Gentamicin Natural products 0.000 description 1
• 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
• 239000012981 Hank's balanced salt solution Substances 0.000 description 1
• 241000590002 Helicobacter pylori Species 0.000 description 1
• 108010054147 Hemoglobins Proteins 0.000 description 1
• 102000001554 Hemoglobins Human genes 0.000 description 1
• 208000034991 Hiatal Hernia Diseases 0.000 description 1
• 206010020028 Hiatus hernia Diseases 0.000 description 1
• 208000031361 Hiccup Diseases 0.000 description 1
• 101100099884 Homo sapiens CD40 gene Proteins 0.000 description 1
• 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 description 1
• 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
• 208000012659 Joint disease Diseases 0.000 description 1
• 241000282838 Lama Species 0.000 description 1
• 108090001030 Lipoproteins Proteins 0.000 description 1
• 102000004895 Lipoproteins Human genes 0.000 description 1
• 101710125418 Major capsid protein Proteins 0.000 description 1
• PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical group O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
• 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
• 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
• 108010006035 Metalloproteases Proteins 0.000 description 1
• 102000005741 Metalloproteases Human genes 0.000 description 1
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical group ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
• SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
• 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 101710141454 Nucleoprotein Proteins 0.000 description 1
• 108010047956 Nucleosomes Proteins 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 108091006033 O-glycosylated proteins Proteins 0.000 description 1
• 208000014174 Oesophageal disease Diseases 0.000 description 1
• 208000003076 Osteolysis Diseases 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 208000008469 Peptic Ulcer Diseases 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• 241000425347 Phyla <beetle> Species 0.000 description 1
• 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
• 108010040201 Polymyxins Proteins 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 208000032395 Post gastric surgery syndrome Diseases 0.000 description 1
• 101710083689 Probable capsid protein Proteins 0.000 description 1
• 102000002067 Protein Subunits Human genes 0.000 description 1
• 108010001267 Protein Subunits Proteins 0.000 description 1
• 208000028017 Psychotic disease Diseases 0.000 description 1
• IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
• NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
• 101150055709 SNF1 gene Proteins 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
• 208000006045 Spondylarthropathies Diseases 0.000 description 1
• 101710172711 Structural protein Proteins 0.000 description 1
• 239000012505 Superdex™ Substances 0.000 description 1
• 230000024932 T cell mediated immunity Effects 0.000 description 1
• 230000037453 T cell priming Effects 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 108090001109 Thermolysin Proteins 0.000 description 1
• WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
• 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
• 108010059993 Vancomycin Proteins 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 208000027207 Whipple disease Diseases 0.000 description 1
• 238000002441 X-ray diffraction Methods 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 108010076089 accutase Proteins 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 230000033289 adaptive immune response Effects 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 230000001270 agonistic effect Effects 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
• 229960003805 amantadine Drugs 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 229960004821 amikacin Drugs 0.000 description 1
• LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
• 230000006229 amino acid addition Effects 0.000 description 1
• 150000003862 amino acid derivatives Chemical class 0.000 description 1
• 229940009444 amphotericin Drugs 0.000 description 1
• 229960003942 amphotericin b Drugs 0.000 description 1
• 239000012491 analyte Substances 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 229940124599 anti-inflammatory drug Drugs 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 230000007503 antigenic stimulation Effects 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
• 239000012131 assay buffer Substances 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
• 229960003071 bacitracin Drugs 0.000 description 1
• 229930184125 bacitracin Natural products 0.000 description 1
• CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 229940125388 beta agonist Drugs 0.000 description 1
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
• 238000010256 biochemical assay Methods 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 230000006287 biotinylation Effects 0.000 description 1
• 238000007413 biotinylation Methods 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 235000011148 calcium chloride Nutrition 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 239000012830 cancer therapeutic Substances 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 238000012054 celltiter-glo Methods 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000008614 cellular interaction Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 229940124587 cephalosporin Drugs 0.000 description 1
• 150000001780 cephalosporins Chemical class 0.000 description 1
• 230000003196 chaotropic effect Effects 0.000 description 1
• 229960005091 chloramphenicol Drugs 0.000 description 1
• WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
• 229960002227 clindamycin Drugs 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 206010009887 colitis Diseases 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 230000009137 competitive binding Effects 0.000 description 1
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
• 230000002153 concerted effect Effects 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 239000007822 coupling agent Substances 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 238000002447 crystallographic data Methods 0.000 description 1
• MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
• 229960003077 cycloserine Drugs 0.000 description 1
• 231100000409 cytocidal Toxicity 0.000 description 1
• 230000000445 cytocidal effect Effects 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 239000000824 cytostatic agent Substances 0.000 description 1
• 230000001085 cytostatic effect Effects 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• 230000009849 deactivation Effects 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 150000002019 disulfides Chemical class 0.000 description 1
• 208000007784 diverticulitis Diseases 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 230000007783 downstream signaling Effects 0.000 description 1
• 201000004997 drug-induced lupus erythematosus Diseases 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 230000012202 endocytosis Effects 0.000 description 1
• 210000001163 endosome Anatomy 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 229960003276 erythromycin Drugs 0.000 description 1
• 208000028299 esophageal disease Diseases 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 201000005884 exanthem Diseases 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 238000001917 fluorescence detection Methods 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 238000003197 gene knockdown Methods 0.000 description 1
• 229960002518 gentamicin Drugs 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 210000000585 glomerular basement membrane Anatomy 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 125000003712 glycosamine group Chemical group 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 229940037467 helicobacter pylori Drugs 0.000 description 1
• 239000000185 hemagglutinin Substances 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 229920001477 hydrophilic polymer Polymers 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 229960004716 idoxuridine Drugs 0.000 description 1
• 229960002182 imipenem Drugs 0.000 description 1
• ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
• 229960001936 indinavir Drugs 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 208000002551 irritable bowel syndrome Diseases 0.000 description 1
• 201000008222 ischemic colitis Diseases 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 229960003350 isoniazid Drugs 0.000 description 1
• QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
• 230000000155 isotopic effect Effects 0.000 description 1
• 229960000318 kanamycin Drugs 0.000 description 1
• 229930027917 kanamycin Natural products 0.000 description 1
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
• 229930182823 kanamycin A Natural products 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
• 229920001427 mPEG Polymers 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 210000001806 memory b lymphocyte Anatomy 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
• 229960004503 metoclopramide Drugs 0.000 description 1
• 229960000282 metronidazole Drugs 0.000 description 1
• VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 239000003471 mutagenic agent Substances 0.000 description 1
• 210000004897 n-terminal region Anatomy 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
• 229960001180 norfloxacin Drugs 0.000 description 1
• OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 150000003833 nucleoside derivatives Chemical class 0.000 description 1
• 210000001623 nucleosome Anatomy 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 229960000988 nystatin Drugs 0.000 description 1
• VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 208000005963 oophoritis Diseases 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
• 229960004448 pentamidine Drugs 0.000 description 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
• 208000011906 peptic ulcer disease Diseases 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 229960003171 plicamycin Drugs 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 150000004291 polyenes Chemical class 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 229920000915 polyvinyl chloride Polymers 0.000 description 1
• 239000004800 polyvinyl chloride Substances 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 230000001124 posttranscriptional effect Effects 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 239000003805 procoagulant Substances 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 201000001474 proteinuria Diseases 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 239000012521 purified sample Substances 0.000 description 1
• 230000001698 pyrogenic effect Effects 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 206010037844 rash Diseases 0.000 description 1
• 229940044601 receptor agonist Drugs 0.000 description 1
• 239000000018 receptor agonist Substances 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 238000004064 recycling Methods 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 229960000329 ribavirin Drugs 0.000 description 1
• HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
• 125000002652 ribonucleotide group Chemical group 0.000 description 1
• 229960000888 rimantadine Drugs 0.000 description 1
• NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
• 229960000311 ritonavir Drugs 0.000 description 1
• 230000022676 rumination Effects 0.000 description 1
• 208000015212 rumination disease Diseases 0.000 description 1
• 229960001852 saquinavir Drugs 0.000 description 1
• QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 239000013606 secretion vector Substances 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 230000036303 septic shock Effects 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 229960000268 spectinomycin Drugs 0.000 description 1
• UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
• 201000005671 spondyloarthropathy Diseases 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000008227 sterile water for injection Substances 0.000 description 1
• 230000003637 steroidlike Effects 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 229940014800 succinic anhydride Drugs 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000001502 supplementing effect Effects 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 238000012956 testing procedure Methods 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 229940126585 therapeutic drug Drugs 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 230000001732 thrombotic effect Effects 0.000 description 1
• 208000037816 tissue injury Diseases 0.000 description 1
• 230000008427 tissue turnover Effects 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• 229960000707 tobramycin Drugs 0.000 description 1
• NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000010474 transient expression Effects 0.000 description 1
• 238000003146 transient transfection Methods 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 150000003852 triazoles Chemical class 0.000 description 1
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
• VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
• 229960003962 trifluridine Drugs 0.000 description 1
• 238000005829 trimerization reaction Methods 0.000 description 1
• 229960001082 trimethoprim Drugs 0.000 description 1
• IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
• 229960003165 vancomycin Drugs 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 238000011179 visual inspection Methods 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
• 229920003169 water-soluble polymer Polymers 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1